Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Bryan Wahl Sells 4,084 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 4,084 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total transaction of $283,511.28. Following the transaction, the general counsel owned 72,315 shares of the company’s stock, valued at $5,020,107.30. This trade represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 19th, Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $67.00, for a total value of $283,477.00.
• On Wednesday, March 18th, Bryan Wahl sold 4,125 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $68.71, for a total value of $283,428.75.

Tarsus Pharmaceuticals Trading Down 2.2%

Shares of TARS stock opened at $66.75 on Friday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25. The stock’s fifty day simple moving average is $69.36 and its 200 day simple moving average is $70.18. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $2.84 billion, a P/E ratio of -41.20 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

TARS has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Guggenheim raised their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Mizuho initiated coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Finally, Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $91.83.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Comerica Bank boosted its holdings in shares of Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after buying an additional 705 shares in the last quarter. Truvestments Capital LLC increased its stake in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after acquiring an additional 468 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after acquiring an additional 172 shares during the period. Osaic Holdings Inc. lifted its position in shares of Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after acquiring an additional 2,462 shares during the period. Finally, Leonteq Securities AG bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth $164,000. 90.01% of the stock is currently owned by institutional investors.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published tighter quarterly and FY‑2026 EPS forecasts (smaller expected losses vs. consensus), which supports a more constructive growth/recovery thesis for the stock. Read More.
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s upgrade improves outlook but does not represent unanimous conviction across all analysts. Read More.
• Neutral Sentiment: Company fundamentals: most recent quarter showed a slight EPS miss (reported ($0.20) vs. ($0.19) estimate) but revenue beat, leaving fundamentals mixed and dependent on future trial/launch catalysts. Read More.
• Neutral Sentiment: High institutional ownership (~90%) is a double‑edged factor — it stabilizes float but means large holders can move the stock if they adjust positions. Read More.
• Negative Sentiment: Significant insider selling disclosed in multiple Form 4s between Mar 16–19: CEO Bobak Azamian sold ~10.9k–12.0k shares across several days (prices ~ $67–$69), director William J. Link sold 12,500 shares (~$68.79), and several other senior officers also reduced stakes — these large, clustered sales can create immediate downward pressure and raise questions about near‑term liquidity needs or portfolio rebalancing. Read More.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.